奧賽康(002755.SZ):子公司AskGene在2023年國際胃癌大會公佈創新藥ASKB589最新研究數據
格隆匯6月16日丨奧賽康(002755.SZ)公佈,公司的子公司ASKGENE PHARMA,INC(簡稱“AskGene”)於2023年6月16日在第十五屆國際胃癌大會(簡稱“2023 IGCC”)上以口頭彙報形式公佈了在研生物創新藥ASKB589注射液(靶向CLDN18.2單克隆抗體)用於實體瘤患者的I/II期多中心試驗(NCT04632108)最新研究結果。
靶向CLDN18.2單克隆抗體ASKB589用於實體瘤患者的I/II期多中心試驗(A Phase I/II Study of ASKB589(Anti-CLDN 18.2 Monoclonal Antibody)in Patients with Solid Tumors)。
截至2023年4月25日,ASKB589臨牀II期擴組研究中,有可測量病灶且至少有過一次治療後腫瘤評估的24例具CLDN18.2中高表達的患者接受了6mg/kg和10mg/kg的ASKB589聯合CAPOX治療,經研究者確認的客觀緩解率(cORR)為79.2%,疾病控制率(DCR)達95.8%。
在顯示深度且持續的抗腫瘤活性的同時,ASKB589擁有良好的安全性及耐受性。截至2023年4月25日,ASKB589I/II期臨牀研究共入組106例患者,單藥治療劑量遞增至20mg/kg,聯合化療劑量遞增至15mg/kg,無病人出現劑量限制性毒性反應(DLT),且尚未達到最大耐受劑量(MTD)。擴組研究中,接受6mg/kg和10mg/kgASKB589聯合CAPOX的治療中均呈現了良好的耐受性,出現的不良事件大多為1-2級以及與化療相關的毒性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.